Taylor Wessing advises Innate Pharma on the in-licence of a phase 1 monoclonal antibody from Novo Nordisk
Taylor Wessing's Life Sciences & Healthcare Group has advised Innate Pharma (IPH) on an agreement with Novo Nordisk, in which Innate Pharma has been granted full development and commercial rights for IPH 2101, a monoclonal antibody in phase 1 cancer clinical trials.
Innate Pharma is a biopharmaceutical company developing first-in-class drugs targeting the innate immune system. This agreement provides Innate Pharma with full rights to IPH 2101 (the first compound developed as a result of the collaboration between Innate Pharma and Novo Nordisk) in exchange of full rights to IPH 2301, plus 2.5 million euros upfront payment, milestone payments and royalties on future sales of IPH 2101.
IPH 2101 is a fully human monoclonal antibody with a novel mechanism of action currently undergoing Phase I clinical trials in hematological cancers; it was recently elected as one of the top 100 great investigational drugs by the R&D Directions magazine. With this second clinical-stage compound, Innate Pharma reinforces its pioneering position in innate immunity and its product portfolio in hematological cancers.
Taylor Wessing is at the cutting edge of work in the life sciences arena. The firm is top ranked in the Pharmaceuticals and Biotechnology section of UK Legal 500, top ranked in the Life Sciences section of UK Chambers, top ranked in the IP and Commercial and Partnering sections of Practical Law Company’s Life Sciences Handbook and was voted European Life Sciences IP Firm of the Year at the Managing Intellectual Property Awards 2008.
Malcolm Bates, Ph.D., partner and head of Taylor Wessing's Life Sciences & Healthcare Group, advised Innate Pharma, along with Tim Worden, Yohan Liyanage and Loretta Pugh
Malcolm comments:
"Having advised Innate Pharma for many years on their long-standing collaboration with Novo Nordisk we are delighted to have been able to assist them on this major strengthening of their development pipeline."
Ends
Notes to editors
For more information please contact Sarah le Cheminant at Taylor Wessing:
Tel: +44 (0)20 7300 4930
Email: s.lecheminant@taylorwessing.com
Taylor Wessing's extensive Life Sciences & Healthcare Group is a multi-disciplinary group combining lawyers from Taylor Wessing’s intellectual property, corporate, competition, dispute resolution, employment and real estate practices. The Group’s clients include Abbott, Amgen, Biocompatibles, Biota and Oxford BioMedica.
Taylor Wessing LLP is a leading law firm providing legal support for commercial organisations doing business in Europe, the Middle East and China. Based in Belgium, China, Dubai, France, Germany and the UK, Taylor Wessing provides the full range of legal services to major corporations and growing enterprises.
About Innate Pharma
Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006,
Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class drugs targeting innate immunity.
The pioneering work of Innate Pharma’s scientific founders and research groups has led to the
development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or
indirectly validated in clinical oncology settings.
Besides oncology, Innate Pharma’s drug candidates have development potential in the treatment of
infectious disease and chronic inflammation. Two of the Company's molecules are undergoing clinical
development, the most advanced being today in Phase II trials in cancer and infections.
With its strong scientific position in innate immunity pharmacology, its robust intellectual property
portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.
Based in Marseilles, France, Innate Pharma had 91 employees as of June 30, 2008.